The panel voted 10-4 against approval, with the majority saying the drug's benefit was not sufficient to offset its risks. The panel was evenly divided over whether the drug was in any way effective.

Drug Candidate for Chronic Cough Rejected by FDA Panel — Gefapixant's benefit not clinically meaningful enough, panelists say Drug Candidate for Chronic Cough Rejected by FDA Panel Gefapixant's ...